Conjugate vaccine

A conjugate vaccine is created by covalently attaching a poor (polysaccharide organism) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes of the carrier on the attached antigen. This technique for the creation of an effective immunogen is most often applied to bacterial polysaccharides for the prevention of invasive bacterial disease.

The immune response

Further information: immune system for a general discussion. This article describes aspects needed to understand conjugate vaccines.

During immune recognition of foreign molecules, the external environment is sampled by naive B cells and dendritic cells which have surface receptors that internalize proteins leading to proteolytic digestion. Some of the resulting peptide fragments (T cell epitopes) are reexpressed on the cell surface in association with MHC II molecules. This "loaded" MHC II may be recognized by complementary T cells that are then stimulated to release cytokines. The cytokines stimulate the pre-B cell to do a number of different things. The cell will mature to an antibody-secreting B cell, replicate itself to an enormous extent, follow a maturation pathway that results in improvement of the antibody structure and production of long lived memory B cells. Maturation is responsible for two hallmarks of the immune response: the production of high affinity antibodies and the creation of memory of prior exposure (anamnestic response). Because the immune response is aided by T cells, proteins are "T-dependent antigens".^{[citation needed]}

If the foreign molecule is not a protein, then proteolyic digestion can not occur and the T-dependent pathway described above does not operate. An antigen-specific antibody response can still occur if the antigen has a repetitive structure (i.e. polysaccharide) or is arranged in a repetitive manner (i.e. proteins arranged on a viral capsid) leading these to be called T-independent antigens. Young children have been shown to be unresponsive to T-independent antigens, leaving them particularly susceptible to infection by encapsulated bacteria and certain viral pathogens.^{[citation needed]}

It was recognized early in the 20th century that attaching a hapten to a carrier protein made the hapten immunogenic. This was extended in the work of Harold Jennings, John Robbins and others to polysaccharides. Polysaccharide conjugates bind to polysaccharide-specific pre-B cells and are taken up. Once inside the cell, the protein portion is digested to release T cell epitopes that result in T cell help. The polysaccharide is converted to a T-dependent antigen by the simultaneous presence of the carrier protein.^{[citation needed]}

This technique has allowed the production of several commercially and medically important vaccines (various capsule types of H. influenza, N. meningitidis and S. pneumoniae), as well as numerous experimental vaccines.^{[citation needed]}

References

See also

• Haemophilus influenzae type b (Hib)
• Hib vaccine
• Meningococcal vaccine
• Pneumococcal vaccines
• Immunogenicity
• B cell

External links

• http://nichddirsage.nichd.nih.gov:8080/ar2004/pages/ldmi/biot.htm
• http://www.nrc-cnrc.gc.ca/education/sti-1990s_jennings_e.html